2

H

1

4名連記　P1-21

1.中山＆内田 P1-9

untitled

untitled

ββ 214 215

MacugenInsert01.ai

2

マニュアル面付け.indd

untitled

ｎｓｇ０１－０４／ｋｙ６９５７４９４６０５０００６０１５２

<31315F985F95B62D899C8CA98E8182D982A92E696E6464>

IF_SUPRECUR_N29

! @ # $ % ^ & * ( ) _ + )# ! a s d a s d f g h a s d @ a s d a s # a s d f g h j $ a s d f g h a s d % a s a a s a s a s d f g ^ a s a s a s & a s d f a s d f g h a s d f g a s d f g a s d a s d * s

untitled

PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 22 NO. 1 (35 53) ether-à-go-go + + + + + + + + + > > + > in vivoin vitro In vivo + + + + + + + + in vivo = + = = = + + + + + + + + + + + + + + + + + + +

KRAS KRAS

KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS : KRAS in vitro KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS

2 3 (1) 3 (2) 5 5 (1) 5 (2) 6 (3) 7 (4) 7 (5) (1) 11 (2) (3) 15 (4)

SUMMARY 23 11 14 24 7 31 1 2 3 (1) 3 (2) 5 5 (1) 5 (2) 6 (3) 7 (4) 7 (5) 8 9 10 10 (1) 11 (2) 12 13 14 15 (3) 15 (4) 16 16 16 17 1 2 22 6 4 3 1995 1 17 6 NGO NPO NGO NPO 1 10 23 6 14 3 11 4 NPO 22 6 NPO

日本産科婦人科学会雑誌第64巻第12号

日本医科大学医学会雑誌第7巻第2号

Helicobacter pylori in vitro in vivo in vitro in vivo in vitro in vivo in situ In situ in situ in situ AluI i i e eiii i K K rrr i i i ii i ii e i iie i i i i eae eae tir cest eae tir

ITｿﾘｭｰｼｮﾝ フロンティア2009年12月号

.r.[...X.j...[.X5..-.{..4C

Hiroshima University Graduate School of Biomedical Sciences Streptococcus mutanss. sobrinus S. mutanss. mutanss. sobrinuss. sanguinis S. salivariuss. mitis in vivo S. mutanss. sobrinus S.mutans

計画の立て方1巻とびら.indd

CONTENTS Lesson 1 Lesson 2 Lesson 3 Lesson 4 Lesson 5 Lesson 6 Lesson 7 Lesson 8 Summary 8 10 12 14 16 18 20 22 24 Lesson 1 Lesson 2 Lesson 3 Lesson 4 Lesson 5 Lesson 6 Summary 26 28 30 32 34 36 38 4 Lesson

論文9.indd

Recent topics in surround sound audio Masaki Sawaguchi Summary This paper will describe the recent trends in surround sound system based on the results of various investigations on this topic. According

pressnet_g36ill.indd

CONTENTS 04 06 08 10 12 14 15 16 18 20 21 22 23 24 25 26 28 30 DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA 32 33 34 36 38 40 41 42 DATA DATA DATA DATA DATA DATA 43 02 CONTENTS 04 06 08 10 12 03 TOPICS

日歯雑誌（Ｈ２８・８月号）別刷り／ポスターセッション　とびら

α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α

1

ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０

φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

2007050781......_.L.O...z.W

a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab

<834A8358835E837D83438359837D836A83858341838B2D30312E6169>

01 1 2 3 4 02 03 1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11 12 13 04 1 2 1 2 3 3 05 06 01 02 03 04 01 02 03 04 05 SITE Web Site Welcome to my home page. SITE Web Site Welcome to my home page.

CONTENTS 2 2 3 3 5 5 6 8 9 10 11 13 13 14 1

CONTENTS 2 2 3 3 5 5 6 8 9 10 11 13 13 14 1 PURPOSE 1 SUMMARY 2 2 3 ACTIVITY REPORT 3 4 ACTIVITY REPORT 5 ACTIVITY REPORT 6 ACTIVITY REPORT 7 ACTIVITY REPORT 8 ACTIVITY REPORT 9 ACTIVITY REPORT 10 REPORT

54_5-06-産たより-03.indd

75 2010 A Safty Analysis for Hospitals on Medical Corporation in 2010 Fiscal Year Kenjiro Ide 1 Backgrounds 3Methods 10 2 Goals 2012 2010 2004 2004 8 13 4 4 4 4 Collecting data 1 2010 76 45 3 2 1 2010

RASSF1 RASSF1 EGFR EGFR Nalú Navarro Alvarez In vitro In vivo Aeromonas sobria Vitis coignetiae Meg1/Grb10 CHARLES WILSON MESSO Drosophila melanogaster Arabidopsis thaliana PEECHAPACK SOMYOONSAP peg peg

VOL.74 WINTER2007 CONTENTS CSK GROUP NEWS 20

H I R Y U VOL.74 WINTER2007 A message from the President of CSK HOLDINGS The Corporate Profile VOL.74 WINTER2007 CONTENTS 1 10 14 16 18 CSK GROUP NEWS 20 HIRYU 2007vol.741 2HIRYU 2007vol.74 A message from

サイトメーカー７の概要 — JSM7 マニュアル v1.1.0

14.02EWE55号本文

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~~~~~~~~~~~~~~~~~~~~~~~~ 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

Microarray Data Analysis Tool Ver3.0 Manual.doc

OVERSEAS 2011 SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS

2

2 3 4 5 6 7 3,500 3,000 2,500 2,000 176 514 58 62 581 588 59 764 72 704 47 694 66 64 421 432 188 262 1,500 1,000 2,173 2,215 2,207 2,291 2,204 2,103 1,959 1,918 1,929 500 0 10/04 10/07 10/10 11/01 11/04

日本医科大学医学会雑誌第8巻第1号

Xenopus laevis in situ μ μ Xenopus laevis Xenopus laevis Xenopus laevis UGT1A1 UGT1A1 IL28B KRAS UGT1A1 UGT1A128 UGT UGT1A1 UGT1A128 UGT1A1 286 UGT1A1 UGT1A1 28 6 UGT UGT UGT1A128 UGT IL28B UGT1A1

ダーク・ムーン

Hase Seisyu Official Web Site Sleepless City http://www.hase-seisyu.com/ http://www.hase-seisyu.com2 http://www.hase-seisyu.com3 http://www.hase-seisyu.com4 http://www.hase-seisyu.com5 http://www.hase-seisyu.com6

untitled

20 21 3 20(2008) 4 1 27(2015) 3 31 1 3 1 3 1 3 5 2 4 20(2008) FD AO 1 3 GP 3 12(2000) 21(2009) CUC 15(2003) ISO14001 GP GP 3 19(2007) 1 2 80 2 3 5 2 4 21(2009) 20(2008)FD 3 3 14(2002) 3 4 20(2008) LIVE

VOL.73 SUMMER2007 CONTENTS CSK GROUP NEWS 23

H I R Y U VOL.73 SUMMER2007 A message from the President of CSK HOLDINGS The Corporate Profile VOL.73 SUMMER2007 CONTENTS 1 10 14 18 20 CSK GROUP NEWS 23 HIRYU 2007vol.731 2HIRYU 2007vol.73 A message from

ｽﾗｲﾄﾞ ﾀｲﾄﾙなし

2002 2002 2002 2002 2002 2002 2002 2002 2002 2002 2002 2002 2002 5 30 JABEE JABEE JABEE JABEE 3 5 JABEE JABEE JABEE JABEE JABEE JABEE 4 120 2003 JABEE JABEE JABEE JABEE JABEE JABEE 2002 2002 2002 JABEE

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2

untitled

(1) (2) (3) (4) (5) (6) i ii iii 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 (Ralstonia, Hydrogenovibrio ) (Synechococcus, Spirulina ) (Thiobacillus ) (Rhodobacter, Rhodospirillum ) (Nitrosomonas

TOP MESSAGE BUSINESS SUMMARY

01

FOLLOW US! 232019 2019 9 10 11 2 Implementation report 9:00 18:00 in 23 2019312911 contents 03 06 10 14 16 02 OSAKA AUTOMESSE 2019 開催概要 SUMMARY 開催実績 PERFORMANCE 262,277 76,916 111,030 74,331 OSAKA AUTOMESSE

< A B D862E696E6464>

2016.6 No.51 防災避難訓練および新入寮生歓迎会 GP GPGood Practice 1 27 28 3,028,930 3,068,806 34,772 34,155 8,911 3,360 982,823 761,804 1,477,311 1,730,000 100,541 105,279 104,133 92,800 265,822 217,232 400,000 600,000

Untitled art 3

2004 5 What s Inside 1 2 3 4 6 9 11 12 Visit our site at www.jccc-chi.org MAY 2004 NEWS CHICAGO 2 MAY 2004 NEWS CHICAGO 3 4 NEWS CHICAGO MAY 2004 MAY 2004 NEWS CHICAGO 5 6 NEWS CHICAGO MAY 2004 MAY 2004

CONTENTS 3 4 5 Campus Note 2005 p2 Summary p4 p8 p10 p14 THE DIFFERENCE p16 p18 p22 p26 p28 p30 MAP 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 u icef u e icef ce icef c f icef f icef i i nicef n icef i e

APO LETTER 1

5 11 21 21 19 19 20 15 5 13 17 15 17 12 17 12 1 7 APO LETTER 1 SOGO Pharmacy APO LETTER 2 APO LETTER 3 SOGO Pharmacy APO LETTER 4 Concept Message 1 2 3 4 5 6 7 8 9 10 APO LETTER 5 SOGO Pharmacy No.4 1

DocuCentre-III C3300 / C2200

C3300 / C2200 2 3 50 45 35 35 35 35 G4 G3 Management Ecology Scan Fax Print Copy C3300 / C2200 Product Summary 4 5 SCAN 6 7 COPY 8 9 PRINT 10 FAX 11 SECURITY 12 12 13 13 MANAGEMENT IC Card Gate IC Card

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11

ｎｓｇ０４－２８／ｋｙ２０８６８４３５６１０００４３０７７

δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!

第４章Word版.PDF

80 81 82 2000 2000 1999 60 500 40 1,000 1999 20 1,200 19.7% 2 30 1.0 20 7.0 2000 4 4 65 2027 67 60 2001 2025 65 83 4 2000 10 4 1 11 1993 61.8 1998 37.0 1993 66.7 29.4 1998 42.9 84 500700 1,500 8.04 11.79

11 11 13 13 13 13 14 14 15 16 16 17 17 17 18 18 21 21 23 24 25 25 26 1 26 27 29 34 34 34 35 35 37 39 41 42 42 43 44 44 44 45 46 46 47 47 48 48 49 50 50 50 51 52 52 53 53 54 55 55 55 55 2 56 57 57 58 59

Newman

32 2001 pp.237 297 ISSN 0287 6817 Toshihiko AMEMIYA Kenichi NAITOH Abstract 237 students were asked to evaluate and propose a reform plan of their university campus as a course report of environmental

NIE NIE 4 S 1GP

NIE NIE http://nie.jp/ 1 1 NIE NIE 1 2 10 15 20 2 1 1 3 2 NIE NIE http://nie.jp/ 4 S 1GP 5 6 1 1 1 1 24 2012 4 5 3 NIE NIE http://nie.jp/ 5 1 000 75 150 1 7 8 1 3 5 5 5 6 1 2 2 3 4 NIE NIE http://nie.jp/

Development of Analysis Equipment for the Reprocessing Plant using Microchips Microchip, Analysis, Reprocessing, Thermal Lens, Uranium, Plutonium Development of Analysis Equipment for the Reprocessing

下関市立大学広報第59号

The Shimonoseki City University Public Relations 200910159 2009 2 Café 2009 211010 1000 1700 4F The Shimonoseki City University Public Relations No.59 2009.10.1 2 The Shimonoseki City University Public

日本化学療法学会雑誌第56巻第3号

β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida

ITソリューションフロンティア2009年8月号

µ µ µ µ

Title 東 京 歯 科 大 学 研 究 年 報 : 平 成 15 年 度 Journal 東 京 歯 科 大 学 研 究 年 報, (): - URL http://hdl.handle.net/10130/388 Right Posted at the Institutional Resources for Unique Colle Available from http://ir.tdc.ac.jp/

http://www.who.int/ipcs/publications/ehc/en/index.html EHC 1 2 3 4 / EHC http://www.nihs.go.jp/dcbi/publist/ehchsg/ 1-8) WHO/IPCS CICAD (Concise Inter

3 [ ] Priority IARC JMPR 2004 10 Priority 1 Priority 1 Priority 2 Priority 3 Priority 1 1-1) CERI) http://www.cerij.or.jp/ceri_jp/koukai/sheet/sheet_indx4.htm http://www.safe.nite.go.jp/data/sougou/pk_list.html?table_name=hyoka&rank=sh

26 No.62 Contents 1 2 3 4 2 No.62

Institute for Traffic Accident Research and Data Analysis INFORMATION 26 No.62 Institute for Traffic Accident Research and Data Analysis 26 No.62 Contents 1 2 3 4 2 No.62 ITARDA INFORMATION Section 1 9

アミヴィッド静注 CTD 第 2 部 2.1 第 2 部から第 5 部の目次 富士フイルム RI ファーマ株式会社

CTD 第 2 部 富士フイルム RI ファーマ株式会社 ( 空白ページ ) 2 第 2 部 ( モジュール 2): CTD の概要 ( サマリー ) ---------------------------------------------- 第 2 巻 2.2 緒言 2.3 品質に関する概括資料緒言 2.3.S 原薬 (AV-105, ) 2.3.S 原薬 ( フロルベタピル ( 18 F),

untitled

1 80 28 100 11 7-1- 2.49 1.89 1.29 0.69 1 1 10 50-2- 65 2 75 2 85 2 95 2 Aw -3- ( ) ( ) 5 5 0 10 ( ) ( ) ( ) -4- -5- 100 1 4 100 31 HACCP Hazard Analysis Critical Control Points 62 65 30-6- -7- -8- 100

ApeosPort-III C3300 / C2200

Ex; 10% 3 HP ex; 3,000 10 ex; 80

27 11 26 18002000 3 12 JOC 2020 ) Ex; 10% 3 HP ex; 3,000 10 ex; 80 7~8 ex; 6000 2 300 10 PR 5~6 50 2,000 ex; / A3 1 & LGBT 2016/4 50 70~80 2020 400 1 1/2 2 JTB ex; JOC H28 2 2 27 11 30 18002000 3 12 JPC

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,

[ ]...1 [ ] Inverse PCR...2 [ ]...3 [ ]...4 Plasmid PCR Primer...4 PCR...5 PCR 2nd-site mutation...5 Plasmid...6 [ ]...8 Inverse PCR Dpn I

06-12 KOD - Plus- Mutagenesis Kit (Code No. SMK-101) TOYOBO CO., LTD. Life Science Department OSAKA JAPAN 0 [ ]...1 [ ] Inverse PCR...2 [ ]...3 [ ]...4 Plasmid.....4 PCR Primer...4 PCR...5 PCR 2nd-site

平成１３年度内分泌攪乱化学物質のヒトへの健康影響調査研究報告書

. 1,3 4 5. 1 2 NB-1 MCF7 MEIC 1-3 4-6 NB-1 JCRB Japan Cancer Research Bank MCF ATCCAmerican Type Culture Collection 2 19994 212 11 PVDF.22µm 8 2 11 4 4 3 5 1 4 cellsml -1 96 4,6 NB-1 48 MCF7 24 4 5 48

Ⅱ 方法と対象 1. 所得段階別保険料に関する情報の収集 ~3 1, 分析手法

67 論文 要旨 : 1507 キーワード : Ⅰ 緒言 65 2014 89 5 2 3 5 6 2 5 6 3 4 3 4 2006 2015 9 9 68 2018. 3 2015 Ⅱ 方法と対象 1. 所得段階別保険料に関する情報の収集 6 2015 7 2016 2 ~3 1,507 2. 分析手法 69 3 3 3 A B C 3 A 4 1 1 2 2 2014 2014 2014 5

Summary Statement of Business 1 2

p221...w......1_1004

Sox17 Hex Sry Sox9 Sox17 Sox17 Sox18 / In vitro In situ in vivo p- Chlamydia pneumoniae Helicobacter pylori Listeria monocytogenes luxs Mycoplasma pneumoniae Mycoplasma pneumoniae Chlamydia pneumoniae

Nutrition Support Journal 9 NS PHARMACIST NS DIETITIAN NS DIETITIAN Nutrition Support Journal 9 NS DIETITIAN Nutrition Support Journal 9 REVIEW DISEASE-SPECIFIC Key Words Summary REVIEW DISEASE-SPECIFIC

repResultEndureTeam_for_TOTAL

Distance: Official Results Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Date: TIME: Number of Starters:

SAS Enterprise Guideによるデータ解析入門

........ 1 / 70.... SAS Enterprise Guide Kengo NAGASHIMA Laboratory of Biostatistics, Department of Parmaceutical Technochemistry, Josai University 2010 11 16 ........ 2 / 70 (SAS / SAS Enterprise Guide

P099～148（04宮部真由美）.PDF

PowerPoint Presentation

CLC Microbial Genomics Module 株式会社キアゲングローバルインフォマティクスソリューションズ & サポートアプライドアドバンストゲノミクス宮本真理 Ph.D. Filgen WebEx seminar, 2015/07/16 (2015/07/30) 1 Agenda メタゲノミクス解析 製品概要 機能紹介 デモ Filgen WebEx seminar, 2015/07/16

本文（１４Ｑ２段組）２／ＹＡ８０２１Ｃ

! "!" ! " ! "! "!" !"! "!"! "!"! "! "!"!"! "!"!"!"! "! "!"!"! "! "! " !"! "! "!"!"!"! "! " ! "! " !"! "! " !" ! "!"! "!"! "!"!"!" !"!"!"!"!"!"! "!"!" !" ! " sd1 !"! " !"! " !"! " ! " ! " !

7 / 70 8 / 70 SAS Enterprise Guide, Windows SAS, SAS,,,, SAS SAS Enterprise Guide SAS: SAS Enterprise Guide:, SAS SAS Enterprise Guide... 5 / 70 6 / 7

3 / 70 4 / 70 SAS Enterprise Guide (SAS / SAS Enterprise Guide ) Kengo NAGASHIMA Laboratory of Biostatistics, Department of Parmaceutical Technochemistry, Josai University 2010 11 16 1 / 70 2 / 70 SAS

ir資料4 2.ai

Outline of business Outline of business Outline of business Outline of business Achievement transition Achievement transition Achievement transition Achievement transition Achievement transition Profit

Summary Statement of Business 1 2

Corporate Social Responsibility Summary Statement of Business 1 2 Nicca Challenge 2016 3 4 5 6 The Way to Multinational Companies Nicca Challenge 2016 Front Line of Development 7 8 Financial Data 9 10

1 40 53 13 42 22 15 51 43 21 40 79 26 63 37 32 44 14 40 33 53 41 48 24 39 49 38 28 51 32 30 59 17 35 63 100 100 100 2 80 57 1 28 16 2 35 31 3 37 62 3 5 35 21 6 37 67 6 50 27 7 48 32 8 10 3 O157:H7 O139

標準仕様書1.ai

powered by EDA koubou.inc 54,739 2,030 SET PRICE + 250,000 + 50,000 + 200,000 + 50,000 + 30,000 + 25,000 + 15,000 + 30,000 + 50,000 + 15,000 + 60,000 + 30,000 + 50,000 + 60,000 + 30,000 + 50,000 + 20,000

Automatic analyzer for clinical chemistry

225 226 5.1.1 1 Automatic analyzer for clinical chemistry 227 5.1.1 2 228 5.1.2.1 Clinical spectrophotometer 5.1.3 Electrolyte analyzer 229 230 5.1.4 Electrophoresis apparatus 231 BF 5.1.5 1 Immunoassay

1 GP 2000p. 24. 45 11 12 46 1 1 1945 1956 1937 15,230 1948 16,852 3 1968 2

1! 1945 9 GHQ 1,500 1 GP 2000p. 24. 45 11 12 46 1 1 1945 1956 1937 15,230 1948 16,852 3 1968 2 1956 1960 278,002 1946 1947 3 5 8 3 1950 1955 5 1949 133 1957 56 5 GHQ 4 8 1946 TM 1950 52 3 GHQ 1950 3 5

本文／研究発表５

Analysis of User Behavior in Social TV System teleda ABSTRACT NHK R&D/No.134/2012.7 35 36 NHK R&D/No.134/2012.7 NHK R&D/No.134/2012.7 37 38 NHK R&D/No.134/2012.7 NHK R&D/No.134/2012.7 39 40 NHK R&D/No.134/2012.7